Here in the UK, Abiraterone (Zytiga) is not currently offered as a front line treatment alongside ADT (presumably because of the high cost to the NHS) and is only offered once initial hormone treatment has been judged to have ‘failed’. However, as we are all well aware it has become apparent through multiple trials that the most significant benefit that can be wrought from Abiraterone is to get this ‘early’ to potentially push back the point at which the cancer becomes castrate resistant (and therefore extend life).
My father was diagnosed in July of 2017 and so is still in the hormone naive phase (he is receiving ADT and has had 6 cycles of Docetaxel). The hope is that he might have another year before castrate resistance (general consensus is that this ‘window’ lasts 18 months).
My question is what members here feel is meant by ‘early’ in terms of Abiraterone treatment. Do we mean early in that it will need to be provided ASAP after diagnosis or early in that it is provided before castrate resistance (and still be as effective as suggested in the trials). This is important as there is a small (miniscule) chance that the NHS will agree later this year that Abiraterone should be given as standard front line treatment (it is under review by Govt).
Will it mean that my Dad could still receive this ‘early’ as he might do so before he becomes castrate resistant or do members feel that ‘early’ really does mean early and that real benefit would come within starting on Abi within a few months (eg) of diagnosis?
I know that no one here is likely to have an answer to this, but I’d be interested in gathering thoughts and opinions. The word ‘early’ is thrown around a bit in relation to many treatments (incl. Docetaxel chemo) but without much detail on what this means.
Best wishes to all